Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switching to Aflibercept 8mg in Neovascular AMD
NCT06683950Phase 4Completed
- Sponsor
- Kim's Eye Hospital
- Start
- Oct 2024
- Primary completion
- Jul 2026
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of aflibercept in age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV), sponsored by Kim's Eye Hospital. Primary endpoint: Presence of retinal fluid. Started Oct 2024; status: completed.
02
Drugs
aflibercept
03
Conditions
age-related macular degeneration (AMD)polypoidal choroidal vasculopathy (PCV)
Beyond the preview
Go deeper on NCT06683950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06683950.